PDE4A and chronic obstructive pulmonary disease: Roflumilast is also another PDE4 inhibitor approved for the treatment of inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease, while crisaborole is approved for atopic dermatitis (35).